Veeva Systems (VEEV) Earnings Beat Puts Its Valuation Narrative Back In Focus

What the latest earnings and guidance tell you about Veeva Systems

Veeva Systems (VEEV) just reported quarterly results that came in ahead of analyst expectations and paired them with higher guidance, putting fresh attention on how its AI focused life sciences cloud products are performing.

The company reported second quarter revenue of US$927.96 million compared with US$789.08 million a year earlier. Net income was US$273.43 million compared with US$200.31 million a year ago, with diluted earnings per share of US$1.66 versus US$1.19.

For the first six months of the fiscal year, Veeva Systems posted revenue of US$1.81b compared with US$1.55b a year earlier. Net income for the same period was US$534.37 million compared with US$428.5 million, and diluted earnings per share were US$3.22 versus US$2.56.

Alongside these earnings, management issued guidance for the third quarter ending October 31, 2026, calling for total revenue between US$932 million and US$935 million. For the fiscal year ending January 31, 2027, the company expects total revenue between US$3.68b and US$3.69b.

These figures came with management commentary highlighting AI as a key driver across Veeva Falcon and the broader Vault AI suite. For investors, the combination of guidance, current revenue scale and emphasis on AI based products helps frame how Veeva Systems is positioning itself within life sciences software.

Veeva Systems’ earnings beat and higher guidance arrived alongside a sharp re-rating in the share price, with a 1-day share price return of 15.2% and a 30-day share price return of 40.22% lifting the stock to US$282.13. That recent surge contrasts with a more modest 1-year total shareholder return of 3.6% and a 5-year total shareholder return that declined 10.7%, which suggests the latest AI driven contract wins and guidance update have recently shifted how the market is pricing the company’s growth and risk profile.

Ride the momentum from Veeva Systems’ AI driven contracts to compare it with other potential breakout opportunities in 74 profitable AI stocks that aren’t just burning cash.

After a 40% climb in 30 days and only a small discount to analyst targets and intrinsic value estimates, the real question is whether Veeva Systems is now priced for perfection or still reflecting lingering market caution.

Most Popular Narrative: 26.4% Undervalued

At a last close of $282.13 versus a narrative fair value of $383.14, the most followed view on Veeva Systems suggests there is still a meaningful valuation gap.

The lesson is that quality investors should separate two decisions:

• Is this a business worth owning for many years?

• At what price does the expected return justify committing capital?

Read the complete narrative.

Want to see what is baked into that $383.14 fair value for Veeva Systems? The key ingredients are long run earnings power, measured revenue expansion and disciplined margins that underpin the cash flow profile behind this narrative.

Result: Fair Value of $383.14 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, the Veeva Systems narrative still faces pressure points, including slower technology spending after large pharma mergers and the risk that Falcon adoption or pricing falls short of expectations.

Find out about the key risks to this Veeva Systems narrative.

Another View on Veeva Systems’ Valuation

The narrative fair value of $383.14 suggests Veeva Systems is 26.4% undervalued, yet the current P/E of 45.2x tells a different story. It is higher than the global Healthcare Services industry at 27.9x and also above a fair ratio of 32x, which implies less room for error if growth expectations ease. How comfortable are you paying a premium multiple for a stock already priced well above its own fair ratio?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Curious whether the current optimism around Veeva Systems matches your own read of the numbers and risks described here? Take a closer look at the underlying data, pressure test your thesis, and then review the 3 key rewards.

Looking for more investment ideas beyond Veeva Systems?

If Veeva Systems has sharpened your focus, do not stop here. Use the Simply Wall St screener to surface other clear opportunities that could fit your portfolio.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include VEEV.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com